Elena Laakmann1, Kerstin Riecke2, Yvonne Goy3, Jan F Kersten4,5, Andreas Krüll6, Volkmar Müller7, Cordula Petersen8, Isabell Witzel9. 1. Department of Gynecology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. e.laakmann@uke.de. 2. Department of Gynecology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. Kerstin.riecke@stud.uke.uni-hamburg.de. 3. Department of Radiotherapy, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. y.goy@uke.de. 4. Department of Medical Biometry and Epidemiology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. j.kersten@uke.de. 5. Department of Biometrics and Statistics, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. j.kersten@uke.de. 6. Department of Radiotherapy, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. kruell@uke.de. 7. Department of Gynecology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. v.mueller@uke.de. 8. Department of Radiotherapy, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. cor.petersen@uke.de. 9. Department of Gynecology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany. iwitzel@uke.de.
Abstract
PURPOSE: Several prognostic indices (PI) have been developed to stratify patients with brain metastases in groups with good or bad prognosis. The aim of our study was to compare nine prognostic scores for patients with brain metastases (BM) of breast cancer receiving radiotherapy. METHODS: The clinical data of 139 breast cancer patients with BM were collected retrospectively. All patients were treated with cerebral radiotherapy or surgery followed by radiotherapy between January 2007 and December 2012. The prognostic value and accuracy of recursive partitioning analysis (RPA), RPA II, graded prognostic assessment (GPA), basic score for BM, Breast-RPA, Breast-GPA, Rades Score 2011, Germany Score and Breast Rades Score were assessed. RESULTS: The median survival after BM diagnosis in our cohort was 14 months. The overall 6-month, 1-, 2- and 3-year survival rates were 49.6, 37.4, 20.9 and 13.7 %, respectively. Most of the PI were associated with OS, but univariate analysis favored GPA regarding OS. GPA was the most accurate score to identify patients with long (longer than 12 months) and Breast-GPA patients with short (<3 months) life expectancy. CONCLUSIONS: GPA and Breast-GPA seem to be the most useful scores and perform better than other PI for breast cancer patients with BM receiving radiotherapy.
PURPOSE: Several prognostic indices (PI) have been developed to stratify patients with brain metastases in groups with good or bad prognosis. The aim of our study was to compare nine prognostic scores for patients with brain metastases (BM) of breast cancer receiving radiotherapy. METHODS: The clinical data of 139 breast cancerpatients with BM were collected retrospectively. All patients were treated with cerebral radiotherapy or surgery followed by radiotherapy between January 2007 and December 2012. The prognostic value and accuracy of recursive partitioning analysis (RPA), RPA II, graded prognostic assessment (GPA), basic score for BM, Breast-RPA, Breast-GPA, Rades Score 2011, Germany Score and Breast Rades Score were assessed. RESULTS: The median survival after BM diagnosis in our cohort was 14 months. The overall 6-month, 1-, 2- and 3-year survival rates were 49.6, 37.4, 20.9 and 13.7 %, respectively. Most of the PI were associated with OS, but univariate analysis favored GPA regarding OS. GPA was the most accurate score to identify patients with long (longer than 12 months) and Breast-GPA patients with short (<3 months) life expectancy. CONCLUSIONS: GPA and Breast-GPA seem to be the most useful scores and perform better than other PI for breast cancerpatients with BM receiving radiotherapy.
Entities:
Keywords:
Brain metastases; Breast cancer; Prognostic score
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Isabell Witzel; Eva Johanna Kantelhardt; Karin Milde-Langosch; Maike Ihnen; Julia Zeitz; Nadia Harbeck; Fritz Jänicke; Volkmar Müller Journal: Onkologie Date: 2011-05-13
Authors: Jaap D Zindler; George Rodrigues; Cornelis J A Haasbeek; Patricia F De Haan; Otto W M Meijer; Ben J Slotman; Frank J Lagerwaard Journal: Radiother Oncol Date: 2013-03-20 Impact factor: 6.280
Authors: A Berghoff; Z Bago-Horvath; C De Vries; P Dubsky; U Pluschnig; M Rudas; A Rottenfusser; M Knauer; H Eiter; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger; M Preusser; R Bartsch Journal: Br J Cancer Date: 2012-01-10 Impact factor: 7.640
Authors: Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2020-02-19 Impact factor: 7.038
Authors: C Fabregat-Franco; A Stradella; V Navarro; J Linares; M Galdeano; S Recalde; R Velasco; M Simo; A Fernadez; A C Venthecourt; C Falo; S Vazquez; M Bergamino; R Villanueva; S Pernas; M J Gil-Gil Journal: Clin Transl Oncol Date: 2021-03-11 Impact factor: 3.405